ECONOMIC EVALUATION OF PREVENTING RSV IN GUATEMALAN INFANTS THROUGH MATERNAL BIVALENT RESPIRATORY SYNCYTIAL VIRUS STABILIZED PREFUSION F (RSVPREF) VACCINATION: A COST-EFFECTIVENESS STUDY
Author(s)
Andreina Jose Alamo, BSc1, Jair A. Arciniegas, MSc2, Jaime Ordoñez, MEd, PhD3, Jorge LaRotta, MD4, Juan José Baldi-Castro, MSc, PharmD5, Leo Alejandro Barrantes, Pharm5, Carlos Grazioso, MD6, Jose M. Leal, MD7, Juan Manuel Reyes, MSc8.
1PFIZER COLOMBIA, Bogota, Colombia, 2Value & Evidence Coordinator, Pfizer SAS, Bogotá, Colombia, 3TrueConsulting, MEDELLIN, Colombia, 4Pfizer SAS, Colombia, Bogotá, Colombia, 5Pfizer, CAC, Escazú, Costa Rica, 6Grupo pediátrico de Guatemala, Guatemala city, Guatemala, 7Little Heroes Pediatric Clinic, Guatemala city, Guatemala, 8Pfizer SAS, Bogotá, Colombia.
1PFIZER COLOMBIA, Bogota, Colombia, 2Value & Evidence Coordinator, Pfizer SAS, Bogotá, Colombia, 3TrueConsulting, MEDELLIN, Colombia, 4Pfizer SAS, Colombia, Bogotá, Colombia, 5Pfizer, CAC, Escazú, Costa Rica, 6Grupo pediátrico de Guatemala, Guatemala city, Guatemala, 7Little Heroes Pediatric Clinic, Guatemala city, Guatemala, 8Pfizer SAS, Bogotá, Colombia.
OBJECTIVES: Assess the cost-effectiveness of the RSVpreF maternal vaccine in infants in Guatemala.
METHODS: A Markov model was adapted to evaluate the RSVpreF maternal vaccine vs. no intervention for lower respiratory tract disease due to respiratory syncytial virus (RSV-LRTD) prevention in Guatemalan infants over life expectancy. RSVpreF is the only maternal immunization option available through the PAHO Revolving-Fund, and no intervention is the current strategy for the overall infant population. The uptake of 55% was based on maternal TDAP coverage in the country. Quality-adjusted life years (QALY) were calculated based on the estimated occurrence of clinical events, such as death, hospitalization, outpatient and emergency department (ED) visits. The healthcare perspective was adopted, and only direct medical costs were included. A 5% discount rate was used for health and economic outcomes. Scientific literature and national and regional databases were used to inform epidemiological and effectiveness inputs. Costs were sourced from the public insurance company reports, national registries and local clinics. Costs were reported in USD.
RESULTS: Compared to no intervention, RSVpreF was estimated to prevent 928 RSV-LRTD hospitalizations, 4,419 outpatient encounters, 2,514 ED visits and 27 RSV-LRTD related deaths. These benefits translates into 514 additional QALY. Direct medical costs were USD 15.2 million with RSVpreF and USD 19.4 million without intervention. The vaccination immunization program was 7.6 million. This resulted in an incremental cost-effectiveness ratio (ICER) of 6,541 USD per QALY, suggesting that under a 1xGDP per capita (6,820) threshold, RSVpreF was a cost-effective strategy.
CONCLUSIONS: Maternal RSVpreF vaccination is a cost-effective strategy for preventing RSV disease in Guatemalan infants. Its implementation is expected to substantially reduce RSV-related morbidity and mortality, preventing 27 deaths and 928 hospitalizations, while providing additional health benefits at a cost considered acceptable under the selected cost-effectiveness threshold.
METHODS: A Markov model was adapted to evaluate the RSVpreF maternal vaccine vs. no intervention for lower respiratory tract disease due to respiratory syncytial virus (RSV-LRTD) prevention in Guatemalan infants over life expectancy. RSVpreF is the only maternal immunization option available through the PAHO Revolving-Fund, and no intervention is the current strategy for the overall infant population. The uptake of 55% was based on maternal TDAP coverage in the country. Quality-adjusted life years (QALY) were calculated based on the estimated occurrence of clinical events, such as death, hospitalization, outpatient and emergency department (ED) visits. The healthcare perspective was adopted, and only direct medical costs were included. A 5% discount rate was used for health and economic outcomes. Scientific literature and national and regional databases were used to inform epidemiological and effectiveness inputs. Costs were sourced from the public insurance company reports, national registries and local clinics. Costs were reported in USD.
RESULTS: Compared to no intervention, RSVpreF was estimated to prevent 928 RSV-LRTD hospitalizations, 4,419 outpatient encounters, 2,514 ED visits and 27 RSV-LRTD related deaths. These benefits translates into 514 additional QALY. Direct medical costs were USD 15.2 million with RSVpreF and USD 19.4 million without intervention. The vaccination immunization program was 7.6 million. This resulted in an incremental cost-effectiveness ratio (ICER) of 6,541 USD per QALY, suggesting that under a 1xGDP per capita (6,820) threshold, RSVpreF was a cost-effective strategy.
CONCLUSIONS: Maternal RSVpreF vaccination is a cost-effective strategy for preventing RSV disease in Guatemalan infants. Its implementation is expected to substantially reduce RSV-related morbidity and mortality, preventing 27 deaths and 928 hospitalizations, while providing additional health benefits at a cost considered acceptable under the selected cost-effectiveness threshold.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE599
Topic
Economic Evaluation, Epidemiology & Public Health
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Vaccines